Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Slides:



Advertisements
Similar presentations
HAART Mitigates Liver Disease Progression in HIV- Viral Hepatitis Co-infected Men Jennifer Price 1, Eric Seaberg 2, Sheila Badri 3, Mallory Witt 4, Kristin.
Advertisements

Predictors of Change in HIV Risk Factors for Adolescents Admitted to Substance Abuse Treatment Passetti, L. L., Garner, B. R., Funk, R., Godley, S. H.,
1 Effect of Maternal HAART on Postnatal HIV-1 Transmission after Cessation of Extended Infant Antiretroviral Prophylaxis Taha Taha 1, Johnstone Kumwenda.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized.
Lara Stabinski 1, Gregory D. Kirk 2, Steve J Reynolds 1, Ponsiano Ocama 3, Francis Bbosa 4, Melissa Saulynas 2, V. Kiggundu 4, Dave Thomas 2, Ron Gray.
Abstract Objective: The MDCH Oral Health Program implemented the Fluoride Varnish program from October Children from 13 selected Early Head.
A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Anti-Retroviral Therapy (cART) AC Justice* 1,2, S Modur.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Effects of HIV/HCV coinfection on Bone Mineral Density and Structure Amber Wheeler, MD WIHS Scientific Meeting June 30, 2014.
Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPACT) Group PROMISE (BREAST FEEDING) 1077 AAHU STC 2013 Group 2 Cedric Sturdevant,
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Effectiveness of Micronutrient-rich Lipid Nutrient Supplements in Delaying Clinical Progression of HIV in Malawian Adults Heidi Sandige, MD.
Growing up with HIV in resource-rich countries: a case report Rohan Hazra, M.D. Pediatric, Adolescent and Maternal AIDS Branch Eunice Kennedy Shriver National.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Language Impairment in 7-16 Year Old Perinatally HIV-Infected Children Mabel Rice* 1, Paige Williams 2, Kathleen Malee 3, Judith Gravel 4, Howard Hoffman.
Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.
Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.
Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.
High Rates of Vitamin D deficiency among HIV-infected and At-risk Women in the United States Oluwatoyin M Adeyemi, Denis Agniel, Audrey L French, Phyllis.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
The psychological and social sequela of HIV/AIDS infection are devastating to youth and their families. Individuals living with HIV/AIDS must cope with.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Background ●Osteoporosis is characterized by low bone mass leading to increased bone fragility and increase in fracture risk, particularly the vertebrae,
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Case Control Study: An example Depression and the Risk of Out-of-hospital cardiac arrest July, 2005.
A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian co-infection cohort study Laurence Brunet, Erica E. M. Moodie,
Guidelines for Appropriate OAI Data Use December 6, 2007 Yuqing Zhang, Boston University.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
F UNCTIONAL L IMITATIONS IN C ANCER S URVIVORS A MONG E LDERLY M EDICARE B ENEFICIARIES Prachi P. Chavan, MD, MPH Epidemiology PhD Student Xinhua Yu MD.
HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
Date of download: 6/21/2016 From: HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study Ann Intern Med. 2013;158(9):
Identification of Potential Risk Factors for Mother-to- Infant HCV Transmission Slideset on: Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal.
QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,
Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) ( )
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Henry Masur, MD Bethesda, Maryland
Incidence of Insulin Resistance, the Metabolic Syndrome and Lipodystrophy in a 3 Year Cohort of HIV-Infected Patients Starting Antiretroviral Therapy in.
Earlier treatment and lower mortality in infants Initiating ART at
Improvement in post traumatic stress & depressive symptoms in HIV-infected Rwandan women on antiretroviral therapy Mardge H. Cohen, Mary Fabri, Xiaotao.
4th IAS Conference , Sydney, Australia, July 2007
Birth Weight and Preterm Delivery Outcomes of Perinatally vs
MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,
San Francisco Department of Public Health
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
2018 Postgraduate Research Symposium: Exploring opportunities
Public Health Implications
Presentation transcript:

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E, Siberry G, Van Dyke R, Rudy B, Flynn P, and Williams P Bill G. Kapogiannis, MD Maternal and Pediatric Infectious Disease Branch

Background HIV infection may contribute to liver disease, even without viral hepatitis co- infection Potential for ART to also contribute to liver problems Non-invasive surrogate markers of liver fibrosis (FIB-4 and APRI) have been investigated and validated in HIV/HCV co-infected adults but have been less studied in children

Background age x AST FIB-4 = platelet count x ALT AST / AST ULN APRI = x 100 platelet count The FIB-4 index includes age, AST, ALT and platelet count: The APRI is the AST-to-platelet ratio index and includes AST, its upper limit of normal and platelet count: >1.5  mild/moderate fibrosis >3.25  advanced fibrosis >0.5  mild/moderate fibrosis >1.5  advanced fibrosis

Objectives To determine how FIB-4 and APRI measures compare between HIV- infected and uninfected youth aged years Among HIV-infected youth, to determine what are the factors that influence any differences Characterize how these effects behave over time in HIV infected individuals

Methods Reaching for Excellence in Adolescent Care and Health (REACH) – a prospective observational HIV+ and uninfected youth cohort – Sequential behavioral & biomedical assessments and specimen collections from 3/96 – 11/99 PACTG 219/219C – prospective multi-center cohort study of HIV and its treatment in infected infants, children and adolescents – Serial biomedical assessments from 4/93 – 5/07 FIB-4 and APRI measures were evaluated in HIV-mono-infected and HIV-uninfected youth ages years

Methods FIB-4 and APRI measures were compared between HIV-infected and uninfected youth based on single visit Within HIV-infected youth with ≥2 visits – Among those with low baseline scores, we estimated and compared incidence rates of progression to higher scores during follow-up – Using repeated measures mixed effect linear regression modeling, we estimated longitudinal trends in log transformed scores, adjusting for age, gender, exposure category, and BMI z-score

Cross-Sectional Analysis Univariate analysis for APRI>0.5: males, HIV+, BMI Z score, CD4, VL & ART [all p<0.002] Adjusted models: Among the entire sample, being HIV-infected and male, and having a low BMI Z score independently predicted an APRI > 0.5 (all p 400) were independent predictors of APRI > 0.5 (all p<0.02)

On evaluation of progression rates of APRI and FIB-4 by cohort (subgroup), there were no statistically significant associations found Longitudinal Analysis

On evaluation of progression rates of APRI and FIB-4 by Baseline HIV VL, there were no statistically significant associations found

Perinatally infected subjects had significant 2% increase in APRI per year Male gender, CD4 400 and those not on ART had consistently higher APRI scores over time (p<0.001) Perinatally infected subjects had significant 2% increase in APRI per year Male gender, CD4 400 and those not on ART had consistently higher APRI scores over time (p<0.001) 2% increase / yr P = 0.007

All HIV-infected participants had significant 6% increase in FIB-4 per year Male gender, CD4 400 and those not on ART had consistently higher FIB-4 scores over time (p<0.001) All HIV-infected participants had significant 6% increase in FIB-4 per year Male gender, CD4 400 and those not on ART had consistently higher FIB-4 scores over time (p<0.001) 6% increase / yr P < 0.001

Limitations No liver biopsy available FIB-4 experience limited to adults FIB-4 and APRI depend on platelet counts which, in general, not as affected in this younger population and thus, scores may potentially underestimate fibrosis severity Cohort and age effects of data abstraction adjusted for but may still have residual unmeasured confounding

Conclusions The mean APRI and FIB-4 scores were higher among HIV-infected youth and remained so after adjustments Among HIV infected youth, progression to values suggesting subclinical fibrosis or worse, was common – IRs for APRI comparable to pediatric studies of younger children – Lower baseline CD4 counts predictive 2-8 x higher IRR (APRI & FIB-4)

Conclusions Differences in score trajectories over time – APRI significantly increased by 2% per year among perinatally infected only – FIB-4 significantly increased by 6% per year among all HIV infected – Male gender, low CD4, detectable VL and not on ART had consistently higher APRI and FIB-4 scores over time

Implications Validation analysis between FIB-4 and APRI for this age group using clinical disease staging and progression is underway More research needed on non-invasive markers in youth, particularly aging up perinatally infected adolescents – Liver stiffness assessment – Novel biochemical markers – Validation with biopsy

Acknowledgments Funding: NICHD (IMPAACT, PHACS, ATN, REACH), NIAID (IMPAACT, PHACS) Collaborators – REACH Craig Wilson – PI – IMPAACT Brooks Jackson - PI – NICHD Rohan Hazra Lynne Mofenson – Harvard School of Public Health PHACS Leadership – Quest Labs Bill Meyer